Organon shareholders approve 7.8 million share increase to 2021 incentive stock plan
At the June 10, 2025 annual meeting, Organon stockholders approved an amended and restated 2021 Incentive Stock Plan that adds 7,800,000 shares for issuance and requires that 95% or more of awards have a one-year minimum vesting period. All 11 director nominees were elected, and the non-binding say-on-pay proposal and the PricewaterhouseCoopers auditor ratification passed, while a stockholder proposal on director resignation was defeated. The larger share reserve could dilute existing shareholders, but the meeting outcomes are otherwise routine.
Key points
- Stockholders approved the Amended and Restated 2021 Incentive Stock Plan, adding 7,800,000 shares, with 154,012,721 votes for and 12,706,870 against.
- All 11 director nominees were elected to serve until the 2026 annual meeting.
- Non-binding say-on-pay proposal passed with 131,520,446 votes for and 35,124,179 against.
- Stockholder proposal on a Director Election Resignation Guideline failed, with 35,267,628 votes for and 131,506,391 against.
The filing
Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 12, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.